Formation of ciprofloxacin nanocrystals within liposomes by spray drying for controlled release via inhalation

Khatib, Isra; Tang, Patricia A.; Ruan, Juanfang; Cipolla, David; Dayton, Francis; Blanchard, James; Chan, Hak‐Kim

doi:10.1016/j.ijpharm.2020.119045

Cited by 20 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a liposome preparation technique based on a bruising change in the pH in which the phospholipids are dilute, causing the liposome to assemble and create a pH-sensitive liposome, this method is called the curvature tuning method [ 105 ] these liposomes have the advantage of being able to deliver not only drugs, but genes inside the cell by the endocytic pathway, being able to be used in therapies for lung cancer [ 106 ]. A single-step and fast method to produce liposomes is the spray-drying method, this technique is simple, the lipids are dissolved in an organic solvent with another compound to protect the phospholipids and then turned into liposomes in the spray-dryer, this method is also suitable for large-scale production and is effective for placing active compounds within liposomes [ 107 ].…”

Section: Nanostructures On Respiratory Therapymentioning

confidence: 99%

Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

Ibarra-Sánchez

Gámez-Méndez

Martínez-Ruiz

et al. 2022

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Section: Nanostructures On Respiratory Therapymentioning

confidence: 99%

Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

Ibarra-Sánchez

Gámez-Méndez

Martínez-Ruiz

et al. 2022

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

“…Hence, this controlled release nanocrystal liposomal formulation can be adequately used for bacterial infection in the lungs. 65 In another investigation, Keil et al developed SD polyplexes formed by polyethylenimine (PEI) and nucleic acids in inert 66 There are also distinct researches reported, e.g., iron oxide incorporated nanoin-microparticles, 67 isoniazid-loaded chitosan NPs, 68 itraconazole-loaded methylcellulose NPs, 69 mag-netic NPs containing sodium alginate and erythropoietin, 70 gefitinib-loaded SLNs, 71 etc., where the SD technique was involved in preparing the particulate matter to accomplish better aerosolization attribute for PDDS.…”

Section: Approaches For the Preparation Ofmentioning

confidence: 99%

“…Nanocrystals exhibit several advantages, such as specific cellular internalization, enhanced particle size distribution, improved stability, etc., making them compelling to be used in pulmonary drug delivery. 196 Ciprofloxacin nanocrystals inside liposomes were formulated using the SD method by Khatib et al 65 for controlled release via inhalation. Sucrose was used as lyoprotectant.…”

Section: Nanoparticles For Chronic Lung Diseasesmentioning

confidence: 99%

“…The characterization study reported EE value ranges between 44 and 87%, volume median diameter of ∼1 μm, fine particle fraction (% wt < 5 μm) of 58–64%, and controlled drug release (80% release within 7 h). Hence, this controlled release nanocrystal liposomal formulation can be adequately used for bacterial infection in the lungs …”

Section: Approaches For the Preparation Of Nanoparticulate Matter For...mentioning

confidence: 99%

See 1 more Smart Citation

Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases

Pramanik

Mohanto

Manne³

et al. 2021

Mol. Pharmaceutics

View full text Add to dashboard Cite

Chronic pulmonary diseases encompass different persistent and lethal diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), asthma, and lung cancers that affect millions of people globally. Traditional pharmacotherapeutic treatment approaches (i.e., bronchodilators, corticosteroids, chemotherapeutics, peptide-based agents, etc.) are not satisfactory to cure or impede diseases. With the advent of nanotechnology, drug delivery to an intended site is still difficult, but the nanoparticle’s physicochemical properties can accomplish targeted therapeutic delivery. Based on their surface, size, density, and physical-chemical properties, nanoparticles have demonstrated enhanced pharmacokinetics of actives, achieving the spotlight in the drug delivery research field. In this review, the authors have highlighted different nanoparticle-based therapeutic delivery approaches to treat chronic pulmonary diseases along with the preparation techniques. The authors have remarked the nanosuspension delivery via nebulization and dry powder carrier is further effective in the lung delivery system since the particles released from these systems are innumerable to composite nanoparticles. The authors have also outlined the inhaled particle’s toxicity, patented nanoparticle-based pulmonary formulations, and commercial pulmonary drug delivery devices (PDD) in other sections. Recently advanced formulations employing nanoparticles as therapeutic carriers for the efficient treatment of chronic pulmonary diseases are also canvassed.

show abstract

“…Schuster et al demonstrated that no noticeable difference in therapeutic effect was found between Colobreathe ® twice daily and nebulized tobramycin (300 mg/5 mL) twice daily (35). Besides commercial products, many other antibiotics have been formulated as dry powders for the treatment of tuberculosis, bronchiectasis and other respiratory diseases, and the developed formulation exhibited acceptable aerosol performance (36)(37)(38). These new formulations may be clinically tested and used in the future.…”

Section: Advantages Of Dpis Usage During Respiratory Supportsmentioning

confidence: 99%

Administration of dry powders during respiratory supports

Ke¹,

Chang²,

Kwok³

et al. 2021

Ann Transl Med

Self Cite

View full text Add to dashboard Cite

Inhaled drugs are routinely used for the treatment of respiratory-supported patients. To date, pressurized metered dose inhalers and nebulizers are the two platforms routinely employed in the clinical setting. The scarce utilization of the dry powder inhaler (DPI) platform is partly due to the lack of in vivo data that proves optimal delivery and drug efficacy are achievable. Additionally, fitting a DPI in-line to the respiratory circuit is not as straightforward as with the other aerosol delivery platforms. Importantly, there is a common misconception that the warm and humidified inspiratory air in respiratory supports, even for a short exposure, will deteriorate powder formulation compromising its delivery and efficacy. However, some recent studies have dispelled this myth, showing successful delivery of dry powders through the humidified circuit of respiratory supports. Compared with other aerosol delivery devices, the use of DPIs during respiratory supports possesses unique advantages such as rapid delivery and high dose. In this review, we presented in vitro studies showing various setups employing commercial DPIs and effects of ventilator parameters on the aerosol delivery. Inclusion of novel DPIs was also made to illustrate characteristics of an ideal inhaler that would give high lung dose with low powder deposition loss in tracheal tubes and respiratory circuits. Clinical trials are urgently needed to confirm the benefits of administration of dry powders in ventilated patients, thus enabling translation of powder delivery into practice.

show abstract

Formation of ciprofloxacin nanocrystals within liposomes by spray drying for controlled release via inhalation

Cited by 20 publications

References 47 publications

Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases

Administration of dry powders during respiratory supports

Contact Info

Product

Resources

About